Plain-English translation of NCT06282445 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether adding a medication called to standard chemotherapy (XELOX) and can help people with advanced colorectal cancer live longer and healthier lives. is an immunotherapy drug that helps your immune system fight cancer cells. The study will compare how well this combination works and what side effects patients experience.
Right now, people with this type of colorectal cancer (called microsatellite stable) have limited treatment options and typically survive only 3 to 4 months. Recent research suggests that adding this medication to standard treatment might extend survival time, so this trial is testing whether that promise holds true in a larger group of patients.
You likely qualify if…
You likely don't qualify if…
You will receive intravenous infusions of the medication combination every 3 weeks for 4 cycles (about 12 weeks). During this time, you'll have imaging scans every 8 weeks to see how your cancer is responding. If your cancer improves or stays stable after 4–6 months, you'll move into a maintenance phase where you continue receiving the medications (at adjusted doses) to keep the cancer under control. Throughout the study, you'll have regular blood tests and check-ins with your care team to monitor for side effects.
AI-generated summary from trial data · Aug 11, 2026 · Not medical advice
China